Back to Journals » International Journal of Nanomedicine » Volume 5

Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis

Authors Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S 

Published 15 September 2010 Volume 2010:5 Pages 525—532


Review by Single anonymous peer review

Peer reviewer comments 2

Safaa Sebak, Maryam Mirzaei, Meenakshi Malhotra, Arun Kulamarva, Satya Prakash
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

Abstract: Drug delivery systems such as nanoparticles can provide enhanced efficacy for ­anticancer agents. Noscapine, a widely used cough suppressant for decades has recently been shown to cause significant inhibition and regression of tumor volumes without any detectable ­toxicity in cells or tissues. Nanoparticles made of human serum albumin (HSA) represent ­promising strategy for targeted drug delivery to tumor cells by enhancing the drug’s bioavailability and distribution, and reducing the body’s response towards drug resistance. In the ­present study, we report for the first time the incorporation and delivery of noscapine-loaded HSA nanoparticles to tumor cells. The nanoparticles were designed and optimized to achieve a particle size in the range of 150–300 nm with a drug-loading efficiency of 85%–96%. The nanoparticles were evaluated in vitro for their anticancer activity and efficacy on breast cancer cells.

Keywords: HSA, encapsulation, microcapsule, nanomedicine, nanotechnology, tumor volumes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.